The Melanoma Content Hub Channel

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

Cancer Center

A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab alone in patients who have had a complete resection of cutaneous melanoma and also have a high-risk of recurrence. The primary endpoint of this trial will be RFS.

Learn more by clicking here.

More in Melanoma Content Hub

►

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

Melanoma Content Hub

Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination of nivolumab...

► 1:45

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

Melanoma Content Hub

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses...

►

Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure

Melanoma Content Hub

Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients...

►

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Melanoma Content Hub

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the assessment of...